Compare DPZ & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPZ | CYTK |
|---|---|---|
| Founded | 1960 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 10.4B |
| IPO Year | 2004 | 2004 |
| Metric | DPZ | CYTK |
|---|---|---|
| Price | $310.75 | $76.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 19 |
| Target Price | ★ $434.29 | $89.26 |
| AVG Volume (30 Days) | 770.6K | ★ 3.1M |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 5.27 | N/A |
| EPS | ★ 4.13 | N/A |
| Revenue | ★ $4,939,994,000.00 | $13,368,000.00 |
| Revenue This Year | $7.98 | $7.37 |
| Revenue Next Year | $3.97 | $310.19 |
| P/E Ratio | $75.60 | ★ N/A |
| Revenue Growth | ★ 4.96 | N/A |
| 52 Week Low | $297.48 | $30.56 |
| 52 Week High | $496.00 | $80.20 |
| Indicator | DPZ | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 59.30 |
| Support Level | $297.48 | $59.07 |
| Resistance Level | $418.07 | $79.66 |
| Average True Range (ATR) | 8.73 | 2.64 |
| MACD | 1.75 | -0.27 |
| Stochastic Oscillator | 48.99 | 60.95 |
Domino's is the world's largest pizza chain, surpassing $20 billion in system sales with over 22,100 stores across more than 90 markets at the end of 2025. Around 33% of its units are in the US. The business is 99% franchised. Domino's operates through three segments: supply chain (60% of revenue), US stores (33%), and international franchises (7%). The firm generates the bulk of its revenue by supplying food to stores in the US and Canada through a vertically integrated network of 25 manufacturing and supply chain facilities, which primarily produce and distribute dough, and collecting brand royalties and marketing fees from franchisees. Domino's also generates revenue from sales at company-owned stores.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.